- Production and packaging of high-quality complex injection preparations such as crystal suspensions, oily solutions, highly oxygen-reduced preparations, implants in vials, ready-to-fill syringes, cartridges and ampoules - Processing of highly active substances such as hormones, cytostatics and controlled substances on appropriately designed modern equipment - Worldwide supply of EVER Pharma products as well as for third-party customers - Pharmaceutical services (full service for the production and testing of sterile dosage forms; support in development and dossier preparation)
- aseptic or terminally sterilised sterile liquid preparations in ampoules, vials and pre-filled syringes - crystal suspensions - hormone products - sterile implants - anaesthetics - oily solutions -- highly oxygen-reduced injection solutions
- Takeover of Jenapharm (formerly part of VEB Jenapharm, founded in 1950) by pharmaceutical wholesaler GEHE AG (1991). - Takeover by Schering AG (1996). - Takeover of sterile production at the Jena site by HEXAL AG and company name as a subsidiary under JENAHEXAL Pharma GmbH (2001). - JENAHEXAL becomes part of the Sandoz Division within the Novartis Group (2005/06). - Takeover of the sterile production JENAHEXAL by EVER Pharma GmbH and company name as a subsidiary under EVER Pharma Jena GmbH (2011). - Investment of over €200 million in state-of-the-art production facilities for injectable products in Jena by EVER Pharma (2015-2021).
EU-GMP Directive 2003/94/EC, ISO 14001, GCC (MENA), CFDA (China), ANVISA (Brazil), RU-GMP (Russia), KFDA (South Korea), TDMDA (Turkey), NDA (Uganda), UAE (United Emirates) and PDMA (Japan)
